Results demonstrate that DIAG723, the Company's lead clustering antibody, can prevent PAH, offering the potential as a first-in-class PAH treatment WATERTOWN, Mass., Sept. 29, 2025 /PRNewswire/ -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling...
Hence then, the article about diagonal therapeutics to present new preclinical data demonstrating disease modifying potential of diag723 in pulmonary arterial hypertension at 2025 ers congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of DIAG723 in Pulmonary Arterial Hypertension at 2025 ERS Congress )
Also on site :
- 1968 Figure Skating Legend Won the Gold at 19 Years Old After Tragic Plane Crash Devastated Entire U.S. Team
- INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Wix.com Ltd. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit - WIX
- Cult-Favorite Restaurant Chain, With the Country's No. 1 Burger, Makes Major Move In-N-Out Has Always Avoided